Search
Nialamide
go.drugbank.com/drugs/DB04820ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.
Rimantadine
go.drugbank.com/drugs/DB00478ApprovedAn RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Sorafenib
go.drugbank.com/drugs/DB00398ApprovedInvestigationalSorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approve...
Fecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigationalFecal microbiota, given either as a rectal transplant or in an oral formulation of live spores, is an FDA-approved option to prevent the recurrence of _Clostridioides difficile_ infection (CDI) in patients
Buserelin
go.drugbank.com/drugs/DB06719ApprovedInvestigationalBuserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
Valaciclovir
go.drugbank.com/drugs/DB00577ApprovedInvestigationalValaciclovir (valacyclovir), also known as _Valtrex_, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades.
Products: VALACICLOVIR MYLAN GENERICSDimethyl sulfoxide
go.drugbank.com/drugs/DB01093ApprovedInvestigationalVet approvedA highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals.
Etomidate
go.drugbank.com/drugs/DB00292ApprovedInvestigationalIt has been proposed as an induction anesthetic.
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic n...
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.